MOMETASONE FUROATE | N019543 | ORGANON LLC A SUB OF ORGANON AND CO
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Completed | Organon and Co | 401 | 2006-05 → 2006-11 | |
| Phase 3 | Completed | Merck Sharp & Dohme LLC | 1,025 | 2015-07-20 → 2018-11-19 | |
| Phase 1 | Completed | Novartis | 24 | 2006-11 | |
| Phase 3 | Completed | Organon and Co | 722 | 2007-04 → 2008-11 | |
| Phase 2 | Completed | Novartis | 31 | 2007-10 → 2008-04 | |
| Phase 2 | Completed | Novartis | 37 | 2007-11 → 2008-04 | |
| Phase 4 | Completed | Organon and Co | 100 | 2004-12-01 → 2005-01-01 | |
| Phase 2 | Completed | Organon and Co | 134 | 2008-05 → 2009-02 | |
| Phase 3 | Completed | Organon and Co | 1,196 | 2006-09 → 2010-07 | |
| Phase 2 | Completed | Organon and Co | 707 | 2007-07 → 2008-02 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
20 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jul 7, 2026 | SUPPL -29 | View Letter (PDF) |
| May 24, 2018 | SUPPL -28 | View Letter (PDF) |
| Apr 1, 2013 | SUPPL -24 | View Letter (PDF) |
| Jun 3, 2004 | SUPPL -14 | View Letter (PDF) |
| Jul 17, 2002 | SUPPL -13 | View Letter (PDF) |
| Jul 17, 2002 | SUPPL -11 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.